Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Turning Point Therapeutics, Inc. (TPTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/17/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
06/24/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
06/03/2022 8-K Quarterly results
06/03/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
04/13/2022 8-K Investor presentation
Docs: "ADVANCED SOLID TUMORS EXP-1 ROS1"
03/04/2022 8-K Quarterly results
02/28/2022 8-K Quarterly results
02/18/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/18/2022 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "TURNING POINT THERAPEUTICS PROVIDES UPDATES AND ANTICIPATED 2022 CLINICAL AND DISCOVERY PIPELINE MILESTONES Strong enrollment within multi-cohort TRIDENT-1 Phase 2 registration enabling study of repotrectinib; completion of targeted 60 patients within EXP-4 ROS1+ TKI-pretreated NSCLC cohort TRIDENT-1 topline BICR ORR and DOR data from ROS1+ NSCLC cohorts and pre-NDA discussion anticipated in 2Q 2022 Phase 1 TRIDENT-1 data in ROS1+ TKI-naïve NSCLC patients continue to show best-in-class potential with DOR range of 5.6-42.2+ months with 3 of 6 responding patients with DOR of greater than 30 months Elzovantinib investigation in Phase 1 SHIELD-1study progresses in dose expansion and with intermediate dose with intention of revising study into a potentially registrational Phase 1/2 study a..."
11/09/2021 8-K Quarterly results
Docs: "TURNING POINT THERAPEUTICS REPORTS THIRD-QUARTER FINANCIAL RESULTS, PROVIDES OPERATIONAL UPDATES"
10/13/2021 8-K Entry into a Material Definitive Agreement  Interactive Data
10/08/2021 8-K Investor presentation
Docs: "4,5 6 4,7-8 9-12 4,5 13-15 4,16"
10/07/2021 8-K Investor presentation
Docs: "54 31 NSCLC, 9 GC/GEJ, 5 CRC, 9"
08/09/2021 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "TURNING POINT THERAPEUTICS REPORTS SECOND-QUARTER FINANCIAL RESULTS, PROVIDES OPERATIONAL UPDATES"
06/29/2021 8-K Quarterly results
06/07/2021 8-K Quarterly results
05/26/2021 8-K Quarterly results
05/25/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
05/05/2021 8-K Quarterly results
04/13/2021 8-K Quarterly results
04/05/2021 8-K Quarterly results
03/31/2021 8-K Quarterly results
03/15/2021 8-K Quarterly results
03/01/2021 8-K Quarterly results
02/17/2021 8-K Quarterly results
01/29/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "TURNING POINT THERAPEUTICS REPORTS UPDATED INTERIM DATA FROM REGISTRATIONAL PHASE 2 TRIDENT-1stUDY OF REPOTRECTINIB IN PATIENTS WITH ROS1-POSITIVE TKI-NAÏVE NON-SMALL CELL LUNG CANCER"
01/11/2021 8-K Quarterly results
12/08/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "TURNING POINT THERAPEUTICS GRANTED FDA BREAKTHROUGH THERAPY DESIGNATION FOR REPOTRECTINIB TREATMENT IN PATIENTS WITH ROS1-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT BEEN TREATED WITH A ROS1 TYROSINE KINASE INHIBITOR"
11/12/2020 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Early Interim Data for TRIDENT-1 Phase 2 Study of Repotrectinib and Second Drug Candidate, TPX-0022, Recently Presented • Phase 2 TRIDENT-1 Registrational Study Full Site Activation and Timeline Update Anticipated in Early 2021 • Four Clinical Studies of Three Drug Candidates Ongoing; Three Additional Clinical Studies Planned in 2021 • Cash, Cash Equivalents, and Marketable Securities of $711 Million and Net Proceeds of Approximately $434 million from Recent Stock Offering Expected to Fund Current Operations into 2024"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy